This disclosure provides chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit epidermal growth factor receptor (EGFR, ERBB1) and/or Human epidermal growth factor receptor 2 (HER2, ERBB2). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) EGFR and/or HER2 activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.
本公开提供化合物(例如,化合物或药物可接受的盐,和/或
水合物,和/或共晶体,和/或化合物的药物组合物),其抑制
表皮生长因子受体(
EGFR,ERBB1)和/或人类
表皮生长因子受体2(HER2,ERBB2)。这些化合物是有用的,例如,用于治疗某种情况,疾病或障碍,在该情况,疾病或障碍中增加(例如过度)的
EGFR和/或HER2激活对该情况,疾病或障碍的病理生理和/或症状和/或进展有贡献的受试者(例如,人类)。本公开还提供包含相同物质的组合物以及使用和制备相同物质的方法。